CP v2

Tag: Depression

  • Cutting Daily TV Time May Lower Depression Risk, With Middle Age Seeing the Biggest Gains

    Cutting Daily TV Time May Lower Depression Risk, With Middle Age Seeing the Biggest Gains

    Reducing time spent watching television and replacing it with more active or restorative habits may lower the risk of major depressive disorder, according to a new study published in European Psychiatry.

    The research suggests the strongest benefits appear in middle-aged adults, while effects are smaller or less consistent among younger and older groups.

    Unlike earlier studies that often linked sedentary behavior to poorer mental health in general, the new analysis focused on what happens when TV time is actively swapped for specific alternatives such as sports, sleep, or other daily activities.

    Lead author Rosa Palazuelos-González of the University of Groningen said the work helps clarify how reallocating screen time, rather than simply reducing it, could influence depression risk over time.

    What the researchers measured

    The study drew on Lifelines, a large Dutch population cohort that followed 65 454 adults who did not have depression at the start of the analysis.

    Participants were tracked for four years, reporting time spent watching TV, sleeping, doing household tasks, commuting, leisure activity, physical activity at work or school, and sports.

    Major depressive disorder was assessed using the Mini International Neuropsychiatric Interview, a structured diagnostic tool widely used in clinical and research settings.

    When researchers modeled a 60-minute shift away from TV toward other activities, they found an 11% lower likelihood of developing major depression across the overall sample.

    In scenarios where 90 or 120 minutes were reallocated, the estimated reduction in likelihood increased, reaching about 25.91% for larger shifts.

    Middle age stands out most

    The largest estimated improvements were seen in middle-aged adults, where replacing one hour of TV per day was associated with an 18.78% lower risk of developing depression.

    In that same age group, reallocating 90 minutes was linked to a 29% reduction, and replacing two hours corresponded to a 43% drop in risk.

    Most substitutions were associated with better outcomes, but swapping only 30 minutes of TV for household chores did not appear to meaningfully change risk.

    By contrast, replacing 30 minutes with sports was associated with an 18% reduction, the biggest improvement among the activities analyzed.

    Why age differences may matter

    Among older adults, the researchers did not find broad, statistically meaningful changes when TV time was redistributed, except when the replacement activity was sports.

    In that group, shifting 30 to 90 minutes from TV to sports was linked to modest decreases in depression probability.

    In younger adults, moving time away from TV toward physical activity did not significantly change depression risk in the models.

    The authors suggested this may be because younger participants tend to be more active overall, potentially already meeting thresholds where additional activity yields smaller mental health benefits.

    The findings do not prove that television causes depression, but they add evidence that how people spend discretionary time may matter, especially in midlife.

    For individuals looking to reduce risk, the results point toward practical substitutions, with sports and other movement-based activities showing the most consistent associations.

  • Study links early depression to brain cell energy changes, hinting at a future blood test

    Study links early depression to brain cell energy changes, hinting at a future blood test

    New research suggests major depressive disorder may be tied to early disruptions in how cells generate and manage energy, a finding that could eventually support earlier and more targeted treatment. Scientists say the results add biological detail to a condition still often diagnosed mainly through symptoms and clinical interviews.

    The study focused on adenosine triphosphate, or ATP, sometimes described as the body’s energy currency because it powers basic cellular work. Researchers examined ATP-related signals in both the brain and blood, aiming to see whether measurable energy patterns track with depression in young adults.

    What the scientists measured

    Teams at the University of Queensland and the University of Minnesota analyzed brain imaging and blood samples from 18 participants aged 18 to 25 diagnosed with major depressive disorder. Their results were compared with samples from people without depression to identify differences linked to the illness.

    According to the researchers, the approach is notable because it looked for matching patterns across the brain and the bloodstream, not just in one system. That raises the possibility that, with more evidence, peripheral markers in blood could one day help flag risk or subtypes of depression earlier.

    An unexpected pattern under stress

    The researchers reported that cells from participants with depression showed higher energy-molecule production while at rest, but had difficulty ramping up energy output when challenged. That stress-response limitation, they argue, could align with common symptoms such as fatigue, slowed thinking, and reduced motivation.

    Scientists involved in the work suggest the pattern may reflect mitochondria that are effectively overcompensating early on, then struggling when demand increases. They caution that the study is small, but say it offers a plausible cellular mechanism worth testing in larger groups.

    What this could mean next

    Major depressive disorder is common and can take years to match with an effective treatment, particularly when fatigue is prominent and persistent. The authors argue that identifying measurable biological signatures could support earlier intervention and more personalized care, rather than trial-and-error alone.

    The research was published in Translational Psychiatry, and the team says follow-up studies are needed to confirm the findings, test whether they predict outcomes, and determine whether they apply across ages and different forms of depression. If replicated, the work could also help frame depression as a whole-body condition with detectable biological changes.

  • UCLA study suggests accelerated TMS may ease treatment-resistant depression in five days, but follow-up timing matters

    UCLA study suggests accelerated TMS may ease treatment-resistant depression in five days, but follow-up timing matters

    Researchers at UCLA Health say an accelerated form of transcranial magnetic stimulation, or TMS, may deliver comparable symptom relief for some people with treatment-resistant depression in just five days. The approach aims to reduce the practical burden of the standard schedule, which typically requires daily weekday visits over six to eight weeks.

    TMS is a noninvasive brain stimulation therapy that uses magnetic pulses to target regions involved in mood regulation. It is commonly offered when patients do not improve after multiple antidepressant trials, and it has become a widely used option in outpatient psychiatric care.

    A five-by-five TMS schedule

    In the study, clinicians compared a compressed protocol known as 5×5, meaning five sessions per day for five consecutive days, with a conventional six-week course. The analysis included 175 patients, with 40 receiving the accelerated format and 135 receiving standard treatment.

    Both groups saw significant reductions in depression symptoms, and overall outcomes were not meaningfully different between schedules. The findings were published in the Journal of Affective Disorders, and the authors noted the results could expand access for patients who struggle to attend weeks of appointments.

    Why follow-up may change results

    One key observation was that some patients in the accelerated group did not appear to improve immediately after the five-day course ended. When assessed again two to four weeks later, those individuals showed substantial improvement, with depression scores falling by an average of 36%.

    That pattern suggests end-of-week assessments may underestimate the benefit of accelerated TMS for certain patients. The researchers said timing could be important when clinicians and patients decide whether a short course is working.

    What the study did not prove

    The researchers cautioned that the comparison was not a randomized clinical trial, meaning patients were not randomly assigned to the accelerated or standard schedule. They also reported that the traditional course performed better on some longer-term measures, underscoring the need for larger controlled trials.

    Even so, the team argues that a shorter TMS pathway could help more eligible patients start and complete care, especially those facing transportation, work, or caregiving barriers. Further research is expected to refine who benefits most, and whether booster sessions after a short course improve durability.

  • Engineered psilocin compound hints at depression relief without hallucinations, early mouse study finds

    Engineered psilocin compound hints at depression relief without hallucinations, early mouse study finds

    Researchers have developed modified versions of psilocin, the active compound produced when the body metabolizes psilocybin, aiming to preserve potential antidepressant effects while reducing psychedelic-like symptoms. The work, published in the Journal of Medicinal Chemistry, adds to a fast-moving effort to make psychedelic-inspired medicines easier to use in routine care.

    Interest in psilocybin has grown as clinical trials explore its potential for major depressive disorder, treatment-resistant depression, anxiety linked to serious illness, and substance use disorders. Yet the hallmark altered state can complicate treatment settings, requiring intensive supervision and limiting who may be willing or able to receive it.

    Why scientists are redesigning psilocin

    The new research focuses on how strongly and how quickly psilocin reaches the brain and activates serotonin receptors, particularly pathways associated with mood regulation. The team tested five chemical variants designed to release psilocin more gradually, potentially reducing the rapid peak linked with more intense psychedelic effects.

    In lab experiments using human plasma and models of gastrointestinal absorption, one candidate stood out for stability and a slower conversion profile. The researchers selected that compound, referred to as 4e, for further testing as a proof of concept rather than a ready-to-use drug.

    What the mouse data suggests

    When given orally to mice, 4e delivered psilocin to the bloodstream and brain over a longer period, with lower peak levels than an equivalent dose of pharmaceutical-grade psilocybin. The compound still crossed the blood-brain barrier efficiently, suggesting it can reach the intended target tissue.

    To estimate psychedelic-like activity, the scientists tracked head-twitch responses, a standard rodent behavioral marker used in serotonin-based psychedelic research. Mice given 4e showed fewer head twitches than those given psilocybin, even though the compound continued to engage key serotonin receptors.

    What comes next before human trials

    The authors argue the results support a broader hypothesis that some therapeutic signaling may be separable from the most disruptive subjective effects. Even so, the study is early, relies on animal behavior proxies, and does not demonstrate antidepressant outcomes in people.

    Next steps typically include deeper safety profiling, dose-ranging studies, and clearer evidence of benefit in validated disease models before any clinical evaluation. The researchers also disclosed industry-linked funding and patent-related interests, which will be important to monitor as the work progresses.

    In parallel, human studies of psilocybin-assisted therapy continue to shape the field, including efforts to standardize dosing, supervision, and outcome measures. If non-hallucinogenic or low-hallucinogenic analogs prove effective, they could eventually broaden access by reducing the need for prolonged monitoring while still targeting serotonin-linked mechanisms relevant to depression.